China's traditional traditional Chinese medicine culture has a history of thousands of years. It has played an important role in the long history of preventing and treating diseases and protecting life and health. The Chinese people have deep feelings for it. However, with the development of history and the advancement of science and technology, traditional Chinese medicine has encountered severe challenges. For example, the active ingredients of the medicine are unclear, the mechanism of action, and adverse reactions are unclear. In short, there is a lack of evidence-based evidence like Western medicine research.
Evidence-based medical research is an internationally recognized scientific method for evaluating the efficacy and safety of drugs. Its main features are the use of large sample, multi-center, randomized, blinded , and controlled methods to test the effectiveness and safety of drugs. "Speaking with evidence", accepting the test of evidence-based medicine, and explaining the efficacy of traditional Chinese medicine in an international language that the world can understand is the only way for the internationalization and modernization of traditional Chinese medicine.
However, it is not easy to carry out evidence-based medical research on traditional Chinese medicine, because evidence-based medical research on post-marketing drugs is risky. Traditional Chinese medicine and Western medicine are completely two theoretical systems. Western medicine experts use current mainstream medical methods to verify the effectiveness of traditional Chinese medicine. If the final result does not have statistical significance and clinical value, the drug will be disapproved and withdraw from the relevant treatment field. risk.
Although it is difficult to carry out evidence-based medical research on traditional Chinese medicine, there are already a few outstanding traditional Chinese medicine companies that are full of confidence in their products and have a strong sense of responsibility for the development of traditional Chinese medicine. They have bravely stepped forward to accept the challenge and promote evidence-based research on traditional Chinese medicine. Integrate with international mainstream medicine and make traditional Chinese medicine truly enter mainstream medicine.
Yiling Pharmaceutical is at the forefront of evidence-based medicine research in traditional Chinese medicine. Since 2005, it has started the research on evidence-based medicine of traditional Chinese medicine and is the first enterprise in my country to carry out evidence-based medicine research.
In 2009, when influenza A H1N1 broke out, researchers launched an evidence-based medical study on " Lianhua Qingwen Capsules for the treatment of influenza A H1N1". The leader unit of this study is Beijing You'an Hospital Affiliated to Capital Medical University. Other units participating in the study include Henan Provincial Infectious Disease Hospital, Hunan Center for Disease Control and Prevention, Shenyang City, Chengdu City, Jinan Infectious Disease Hospital and other nine domestic influenza A treatment hospitals. A large number of cases have been collected across the country, covering patients with influenza A (H1N1) in all major age groups and with various symptoms.
The results of the research are exciting. First of all, Lianhua Qingwen Capsules have no difference from oseltamivir in antiviral effects, and are effective in relieving influenza symptoms, especially reducing fever and relieving cough, headache, muscle aches and fatigue. It is better than oseltamivir in terms of other symptoms. The body temperature onset and body temperature relief time are better than oseltamivir, and the H1N1 virus nucleic acid negative turning time is comparable to oseltamivir.
Another product of the company for the treatment of respiratory diseases Lianhua Qingke Tablets has also joined the evidence-based research, "A randomized double-blind, placebo-controlled, multi-center study of Lianhua Qingke Tablets in the treatment of acute tracheobronchitis "The results show that Lianhua Qingke Tablets has a definite effect of relieving cough and reducing phlegm, and can effectively relieve patients' symptoms such as cough, expectoration, dry throat, thirst, and chest distress. It is also safe for clinical use and provides patients with acute tracheobronchitis." A new treatment option, now a patented innovative traditional Chinese medicine for the treatment of acute tracheobronchitis. In 2022, the international academic journal "Evidence-Based Complementary and Alternative Medicine" published a paper titled "A Randomized Controlled Multicenter Clinical Study on the Efficacy and Safety of Lianhua Qingke Tablets in the Treatment of Mild and Common COVID-19", revealing that The efficacy of Lianhua Qingke in treating COVID-19.
It is precisely because of Yiling Pharmaceutical's innovative research in traditional Chinese medicine evidence-based medicine and the acquisition of a large amount of evidence-based medical evidence that many of its products, such as Lianhua Qingwen Capsules and Lianhua Qingke Tablets, have been included in guides, Expert consensus and disease diagnosis and treatment standards are recommended.For example, the "Beijing New Coronavirus Pneumonia Traditional Chinese Medicine Prevention and Treatment Plan (Trial Version 6)" released by Beijing Administration of Traditional Chinese Medicine on May 6, 2022. Among the treatment drugs recommended in the new plan, Lianhua Qingwen Granules /capsules and Lianhua Qingke tablets are both recommended.
It can be seen that carrying out evidence-based medical research on traditional Chinese medicine is the only way for traditional Chinese medicine to get out of the predicament and integrate into mainstream international medicine.
